Seattle Genetics ends clinical trial after “a higher rate of deaths”

Seattle Genetics said it is discontinuing a Phase 3 clinical trial after data showed “a higher rate of deaths, including fatal infections” in acute myeloid leukemia patients receiving its drug than in the study’s other patients. ...
3 Published By - The Seattle Times - 2017.06.19. 15:46
Share |